H. Davies, G. R. Bignell, and C. Cox, Mutations of the BRAF gene in human cancer, Nature, vol.417, pp.949-954, 2002.

L. A. Fecher, R. K. Amaravadi, and K. T. Flaherty, The MAPK pathway in melanoma, Curr Opin Oncol, vol.20, pp.183-189, 2008.

, Implication of CD271 in melanoma BRAF inhibitor resistance 12

, Cell Discovery | www.nature.com/celldisc

P. B. Chapman, A. Hauschild, and C. Robert, Improved survival with vemurafenib in melanoma with BRAF V600E mutation, N Engl J Med, vol.364, pp.2507-2516, 2011.

K. T. Flaherty, I. Puzanov, and K. B. Kim, Inhibition of mutated, activated BRAF in metastatic melanoma, N Engl J Med, vol.363, pp.809-819, 2010.

J. A. Sosman, K. B. Kim, and L. Schuchter, Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib, N Engl J Med, vol.366, pp.707-714, 2012.

R. Nazarian, H. Shi, and Q. Wang, Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation, Nature, vol.468, pp.973-977, 2010.

J. Villanueva, A. Vultur, and J. T. Lee, Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K, Cancer Cell, vol.18, pp.683-695, 2010.

P. I. Poulikakos, Y. Persaud, and M. Janakiraman, RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E), Nature, vol.480, pp.387-390, 2011.

C. M. Johannessen, J. S. Boehm, and K. Sy, COT drives resistance to RAF inhibition through MAP kinase pathway reactivation, Nature, vol.468, pp.968-972, 2010.

N. Wagle, C. Emery, and M. F. Berger, Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling, J Clin Oncol, vol.29, pp.3085-3096, 2011.

D. Fang, T. K. Nguyen, and K. Leishear, A tumorigenic subpopulation with stem cell properties in melanomas, Cancer Res, vol.65, pp.9328-9337, 2005.

T. Schatton, G. F. Murphy, and N. Y. Frank, Identification of cells initiating human melanomas, Nature, vol.451, pp.345-349, 2008.

D. Thakur, M. Salangsang, F. Landman, and A. S. , Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance, Nature, vol.494, pp.251-255, 2013.

M. P. Smith, B. Sanchez-laorden, O. 'brien, and K. , The immune microenvironment confers resistance to MAPK pathway inhibitors through macrophage-derived TNFalpha, Cancer Discov, vol.4, pp.1214-1229, 2014.

T. Enzler, Y. Sano, and M. K. Choo, Cell-selective inhibition of NF-kappaB signaling improves therapeutic index in a melanoma chemotherapy model, Cancer Discov, vol.1, pp.496-507, 2011.

M. Hinz and C. Scheidereit, The IkappaB kinase complex in NF-kappaB regulation and beyond, EMBO reports, vol.15, pp.46-61, 2014.

J. Landsberg, J. Kohlmeyer, and M. Renn, Melanomas resist T-cell therapy through inflammation-induced reversible dedifferentiation, Nature, vol.490, pp.412-416, 2012.

M. Bibel and Y. A. Barde, Neurotrophins: key regulators of cell fate and cell shape in the vertebrate nervous system, Genes Dev, vol.14, pp.2919-2937, 2000.

T. Redmer, Y. Welte, and D. Behrens, The nerve growth factor receptor CD271 is crucial to maintain tumorigenicity and stem-like properties of melanoma cells, PLoS ONE, vol.9, p.92596, 2014.

Y. Cheli, V. F. Bonnazi, and A. Jacquel, CD271 is an imperfect marker for melanoma initiating cells, Oncotarget, vol.5, pp.5272-5283, 2014.
URL : https://hal.archives-ouvertes.fr/inserm-02530580

G. Civenni, A. Walter, and N. Kobert, Human CD271-positive melanoma stem cells associated with metastasis establish tumor heterogeneity and long-term growth, Cancer Res, vol.71, pp.3098-3109, 2011.

R. Menon, D. Das, S. Krepler, and C. , A stress-induced early innate response causes multidrug tolerance in melanoma, Oncogene, vol.34, pp.4448-4459, 2014.

A. D. Boiko, O. V. Razorenova, and M. Van-de-rijn, Human melanoma-initiating cells express neural crest nerve growth factor receptor CD271, Nature, vol.466, pp.133-137, 2010.

D. J. Konieczkowski, C. M. Johannessen, and O. Abudayyeh, A melanoma cell state distinction influences sensitivity to MAPK pathway inhibitors, Cancer Discov, vol.4, pp.816-827, 2014.

F. Sabbatino, Y. Wang, and X. Wang, PDGFRalpha upregulation mediated by sonic hedgehog pathway activation leads to BRAF inhibitor resistance in melanoma cells with BRAF mutation, Oncotarget, vol.5, pp.1926-1941, 2014.

T. Botton, A. Puissant, and P. Bahadoran, In vitro and in vivo anti-melanoma effects of ciglitazone, J Invest Dermatol, vol.129, pp.1208-1218, 2009.
URL : https://hal.archives-ouvertes.fr/hal-02194090

P. Corazao-rozas, P. Guerreschi, and M. Jendoubi, Mitochondrial oxidative stress is the Achille's heel of melanoma cells resistant to Braf-mutant inhibitor, Oncotarget, vol.4, pp.1986-1998, 2013.

M. Cerezo, M. Tichet, and A. P. , Metformin blocks melanoma invasion and metastasis development in a p53-dependent manner, Mol Cancer Ther, vol.12, pp.1605-1615, 2013.

T. Botton, A. Puissant, and Y. Cheli, Ciglitazone negatively regulates CXCL1 signaling through MITF to suppress melanoma growth, Cell Death Differ, vol.18, pp.109-121, 2011.
URL : https://hal.archives-ouvertes.fr/hal-00551041

T. Tomic, T. Botton, and M. Cerezo, Metformin inhibits melanoma development through autophagy and apoptosis mechanisms, Cell Death Dis, vol.2, p.199, 2011.
URL : https://hal.archives-ouvertes.fr/inserm-02530686